Comparison of the anti-proliferative effects of carboplatin anticancer drugs used for cervical cancer treatment
Keywords:
Cervical cancer, Carboplatin, Chemotherapy, MTT assayAbstract
Cancer is a genetic material abnormality and a major problem cause of death in many countries. Cervical cancer is the third most common in Thai women following breast and colorectal cancers, respectively. Human papilloma virus (HPV) infection is a major cause of cervical cancer, transmitted through sexual contact. Nowadays, HPV vaccines can effectively protect the viral epidemics, but many problems regarding the use and distribution still exist. Chemotherapy plays a major role in standard treatment to inhibit cancer cell growth. However, it has the disadvantages of inducing drug resistance and producing unwanted side effects in patients. The objective of this research was to evaluate the potential anticancer activity of carboplatin against human cervical cancer cells (HeLa cells). Antiproliferative activity of carboplatin was determined at exposure times of 24, 48 and 72 h using MTT assay. The results showed that carboplatin inhibited the growth of HeLa cells with half maximal inhibitory concentrations (IC50 values) of more 400, 244.96 ± 3.33 and 97.60 ± 3.63 µM at 24, 48 and 72 h exposures, respectively. In conclusion, carboplatin exhibited antiproliferative activity against HeLa cells in a dose- and time-dependent manner. This study helps in the design of drug treatments or chemotherapy programs to control cervical cancer cells and reduce side effects in patients.
References
Adams, C. J., & Meade, T. J. (2020). Gd(III)–Pt(IV) theranostic contrast agents for tandem
MR imaging and chemotherapy. Chemical Science, 11(9), 2524-2530.
https://doi.org/10.1039/C9SC05937G
Aggarwal, S., Agarwal, P., & Singh, A. K. (2023). Human papilloma virus vaccines: A comprehensive narrative review. Cancer Treatment and Research Communications, 37, 100780. https://doi.org/10.1016/j.ctarc.2023.100780
Akhlaghi, E., Lehto, R. H., Torabikhah, M., Sharif Nia, H., Taheri, A., Zaboli, E., & Yaghoobzadeh, A. (2020). Chemotherapy use and quality of life in cancer patients at the end of life: An integrative review. Health and Quality of Life Outcomes, 18(1), 332. https://doi.org/10.1186/s12955-020-01580-0
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492
Burmeister, C. A., Khan, S. F., Schäfer, G., Mbatani, N., Adams, T., Moodley, J., & Prince, S. (2022). Cervical cancer therapies: Current challenges and future perspectives. Tumour Virus Research, 13, 200238. https://doi.org/10.1016/j.tvr.2022.200238
Dasari, S., & Bernard Tchounwou, P. (2014). Cisplatin in cancer therapy: Molecular mechanisms of action. European Journal of Pharmacology, 740, 364–378. https://doi.org/10.1016/j.ejphar.2014.07.025
Ghasemi, M., Turnbull, T., Sebastian, S., & Kempson, I. (2021). The MTT Assay: Utility, Limitations, Pitfalls, and Interpretation in Bulk and Single-Cell Analysis. International Journal of Molecular Sciences, 22(23), 12827. https://doi.org/10.3390/ijms222312827
Lei, J., Ploner, A., Elfström, K. M., Wang, J., Roth, A., Fang, F., Sundström, K., Dillner, J., & Sparén, P. (2020). HPV Vaccination and the risk of invasive cervical cancer. New England Journal of Medicine, 383(14), 1340-1348. https://doi.org/10.1056/NEJMoa1917338
Liu, Y., Tergaonkar, V., Krishna, S., & Androphy, E. J. (1999). Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. The Journal of biological chemistry, 274(35), 24819–24827. https://doi.org/10.1074/jbc.274.35.24819
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003). 5-Fluorouracil: Mechanisms of action and clinical strategies. Nature Reviews Cancer, 3(5), 330–338. https://doi.org/10.1038/nrc1074
Okunade, K. S. (2020). Human papillomavirus and cervical cancer. Journal of Obstetrics and Gynaecology, 40(5), 602–608. https://doi.org/10.1080/01443615.2019.1634030
Regalado Porras, G. O., Chávez Nogueda, J., & Poitevin Chacón, A. (2018). Chemotherapy and molecular therapy in cervical cancer. Reports of Practical Oncology & Radiotherapy, 23(6), 533–539. https://doi.org/10.1016/j.rpor.2018.09.002
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Zhong, H., Jin, G., Qi, H., Lou, M., Liu, X., Qu, Y., Zhao, L., Zhang, W., Shao, J., & Zhao, J. (2013). Gemcitabine and carboplatin demonstrate synergistic cytotoxicity in cervical cancer cells by inhibiting DNA synthesis and increasing cell apoptosis. OncoTargets and Therapy, 1707. https://doi.org/10.2147/OTT.S54217
Zon, A. M., Namwan, N., Senawong, S., Nontakitticharoen, M. & Senawong, T. (2025). Antiproliferative activity of alizarin derivative against human cervical cancer cell line. Proceedings of the 2025 International symposium for agricultural biomedical research network: The fusion of natural product chemistry and medical information engineering for advancement of medicine-2025. University Academic Service Center (UNISERV CMU), Chiang Mai University, Chiang Mai, Thailand (pp. 105-111). https://www.agribiomed2025.org/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Faculty of Liberal Art and Science, Roi-Ed Rajabhat University
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของคณะศิลปศาสตร์และวิทยาศาสตร์ มหาวิทยาลัยราชภัฏร้อยเอ็ด
ข้อความที่ปรากฏในบทความแต่ละเรื่องในวารสารวิชาการเล่มนี้เป็นความคิดเห็นส่วนตัวของผู้เขียนแต่ละท่านไม่เกี่ยวข้องกับมหาวิทยาลัยราชภัฎร้อยเอ็ด และคณาจารย์ท่านอื่นๆในมหาวิทยาลัยฯ แต่อย่างใด ความรับผิดชอบองค์ประกอบทั้งหมดของบทความแต่ละเรื่องเป็นของผู้เขียนแต่ละท่าน หากมีความผิดพลาดใดๆ ผู้เขียนแต่ละท่านจะรับผิดชอบบทความของตนเองแต่ผู้เดียว
